Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Remedy Taking a hit why? -- Ignore unavailable to you. Want to Upgrade?

To: Thomas DeGagne who wrote (755)	1/28/2001 10:45:01 AM
From: Qualified Opinion	Respond to of 763

A few points made during the earnings conference call>> Remedy increased its sales force to 370 salesmen currently, up from under 300 salesmen on 9/30/00. They expect to have 390 salesmen by the end of this quarter. They hired a number of experienced salesmen in CRM. It can take up to 6 months to bring the new ones up to full production. They are forecasting a conservative 25% increase in revenue to $360 million for this year . They are reducing their expected effective tax rate to 28% from 30% due to lower tax rates on foreign income. Remember, Remedy should be releasing its web-centic platform product around the middle of this year.

To: Thomas DeGagne who wrote (755)	1/28/2001 11:40:27 AM
From: Qualified Opinion	Read Replies (1) \| Respond to of 763

A few more points made during the earnings conference call>>> Remedy increased its sales force by 30%, 370 salesmen on 1/25/01 versus 285 on 9/30/00. Many of the new sales reps. are from the competition. Remedy has 188 partners under contract. Remedy will be selling solutions by market segment. They can deliver solutions faster than their competition. This enables their customers to adapt quicker to a changing environment. They added 250 new customers during the quarter including Lam Research, Fiat, Nasdaq Japan, Lehman Brothers, Prudential Europe, Capital One, Zurich Bank, Northern States Power and Chicago Stock Exchange to name a few. Remedy has approximately $7 per share in cash on its Balance Sheet.